[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-microsatellite-stable-mss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-microsatellite-stable-mss":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100627271","phase-4-folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmrmss-colorectal-cancer-100627271",false,"NCT07446465","FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR\u002FMSS Colorectal Cancer","Exploratory Clinical Study of FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR\u002FMSS Colorectal Cancer","Inclusion Criteria:\n\n* Age 18-75 years;\n* Histologically confirmed adenocarcinoma of colorectal cancer, initially unresectable locally advanced or metastatic\u002Frecurrent disease;\n* Expected survival ≥12 weeks;\n* No prior systemic antitumor therapy for colorectal cancer;\n* Confirmed pMMR by IHC or MSS\u002FMSI-L by PCR or NGS;\n* ECOG PS 0-1;\n* At least one measurable lesion per RECIST v1.1;\n* Adequate organ and bone marrow function;\n* Controlled viral hepatitis status as specified;\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Prior immune checkpoint inhibitor therapy;\n* CNS or leptomeningeal metastases;\n* Uncontrolled cardiovascular disease or hypertension;\n* Active autoimmune disease requiring systemic therapy;\n* Active infection including tuberculosis;\n* Recent major surgery;\n* Pregnancy or lactation;\n* Any condition deemed by investigators to compromise safety or study compliance.","ALL","18 Years","75 Years",{"count":20,"type":21},42,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","To evaluate the efficacy and safety of immune checkpoint inhibitor-based combination therapy with targeted therapy and chemotherapy in patients with locally advanced unresectable or metastatic colorectal cancer.",[27,28],"Colorectal Cancer (Locally Advanced or Metastatic)","Colorectal Cancer Microsatellite Stable (MSS)","NOT_YET_RECRUITING","2026-02-28",{"date":32,"type":33},"2026-03-03","ACTUAL",{"date":35,"type":21},"2026-03-01",{"date":37,"type":21},"2027-01-31",{"name":39,"class":40},"Ye Xu","OTHER"]